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Abstract
Recombinant adeno-associated viral (AAV) vectors have been shown to be one of the most promising vectors for
therapeutic gene delivery because they can induce efficient and long-term transduction in non-dividing cells with
negligible side-effects. However, as AAV vectors mostly remain episomal, vector genomes and transgene expression
are lost in dividing cells. Therefore, to stably transduce cells, we developed a novel AAV/transposase hybrid-vector.
To facilitate SB-mediated transposition from the rAAV genome, we established a system in which one AAV vector
contains the transposon with the gene of interest and the second vector delivers the hyperactive Sleeping Beauty
(SB) transposase SB100X. Human cells were infected with the AAV-transposon vector and the transposase was
provided in trans either by transient and stable plasmid transfection or by AAV vector transduction. We found that
groups which received the hyperactive transposase SB100X showed significantly increased colony forming numbers
indicating enhanced integration efficiencies. Furthermore, we found that transgene copy numbers in transduced cells
were dose-dependent and that predominantly SB transposase-mediated transposition contributed to stabilization of
the transgene. Based on a plasmid rescue strategy and a linear-amplification mediated PCR (LAM-PCR) protocol we
analysed the SB100X-mediated integration profile after transposition from the AAV vector. A total of 1840 integration
events were identified which revealed a close to random integration profile. In summary, we show for the first time
that AAV vectors can serve as template for SB transposase mediated somatic integration. We developed the first
prototype of this hybrid-vector system which with further improvements may be explored for treatment of diseases
which originate from rapidly dividing cells.
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Introduction
Gene therapy is a rapidly developing field relying on
introduction of nucleic acids into mammalian cells to regulate,
repair, replace, add or delete a genetic sequence. Monogenetic
diseases like hemophilia B, Duchenne muscular dystrophy and
cystic fibrosis are the three most frequent indications for clinical
trials in gene therapy [1]. For life-long correction of genetic
diseases, therapeutic DNA needs to be efficiently delivered to
the respective target tissue and cells and transgene expression
needs to be maintained at a therapeutic level.
Adeno-associated virus (AAV) belongs to the family of
parvoviridae and contains a single-stranded DNA genome of
about 4.7 kilobases (kb) in length. Its genome is flanked by
inverted terminal repeats (ITR) and encodes the two major
open reading frames (ORFs) rep and cap [2]. Known encoded
proteins of rep include Rep78, Rep68, Rep52 and Rep40 and
cap encoded proteins include VP1, VP2 and VP3, and the
assembly-activating protein AAP. Recombinant AAV vectors
lack both ORFs and combine several advantages, including
efficient infectivity, stable transgene expression in quiescent
cells and nonpathogenicity [3]. AAV vectors have been
extensively investigated in preclinical and clinical settings [4]
and they were involved in several clinical trials to treat
metabolic abnormalities, hemophilia disease, Parkinson’s
disease, muscular dystrophy and cystic fibrosis [2,4,5].
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Towards this end several AAV serotypes were explored
showing different tropisms in vivo [6] which significantly
extended applications of AAV vectors for clinical and other
applications.
After in vivo administration, AAV vectors can result in
efficient and long-term transduction of non-dividing cells.
However, as AAV vectors mostly remain episomal, vector
genomes and transgene expression are lost over time in
dividing cells [7]. Therefore, to stably transduce tissues and
cells undergoing cell division, genetic elements for
maintenance of therapeutic DNA need to be combined with the
AAV technology for efficient long-term transgene expression. In
the present study, we developed a novel AAV/transposase
hybrid-vector for somatic integration of the genetic payload
from the AAV vector genomes into the host chromosomes
utilizing the Sleeping Beauty (SB) transposase integration
machinery. The SB transposase system represents a powerful
tool for somatic integration and it was demonstrated that it has
fundamental implementations for experimental and therapeutic
gene transfer approaches [8,9]. The transposable element SB
has been generated from inactive copies of an ancestral Tc1/
mariner-like transposon in fish [8]. In the presence of
transposase supplied in trans, any gene of interest flanked by
inverted repeats (IRs) represents a substrate for transposition
resulting in somatic integration into a TA-dinucleotide [8,10].
Very recently hyperactive SB transposase versions HSB5 [11]
and SB100X [12] were generated by mutagenesis screens
which resulted in 10- and 100-fold increased integration
efficiencies, respectively. Previous data suggest that the target
sites of integration after SB mediated recombination show a
close to random genomic distribution profile. Based on studies
utilizing different delivery vehicles for the SB transposase
system, it was estimated that 39-53% of transposition events
are located in genes [13-15].
Herein, we aimed at establishing AAV vectors for stabilized
transgene expression in mammalian cells. We show for the first
time that AAV vectors can serve as template for SB
transposase mediated somatic integration with a close to
random integration profile.
Results
AAV vectors serve as direct substrates for
transposition
After cellular transduction, AAV vector genomes form various
DNA forms such as episomal circular and linear monomers and
concatemers [16]. For achieving stabilized transgene
expression the goal of this study was to mobilize a transposon
from episomal AAV vector genomes for SB transposase-
mediated stable integration of a transgene expression cassette
into the mammalian host genome (Figure 1).
To assure that all cells express hyperactive SB transposase
SB100X, we first established cell lines stably expressing either
SB100X or inactive SB transposase (mSB). These cell lines
were generated using stable transfection of plasmids pIRES-
Puro-SB100X and pIRES-Puro-mSB (Figure 2a). As shown in
Figure 2b, these cells were tested for transposase expression
on RNA level by reverse transcription and subsequent PCR
analysis. After transfection of the transposon donor plasmid
pTnori and selection of stably transduced cells, SB100X
expressing cells showed a significantly increased number of
colony forming units proving functionality of SB100X in these
cells (Figure 2c). To perform respective experiments with AAV
vectors, we produced the AAV vector AAV-neo containing a
transposon with a neomycin resistance gene for expression in
mammalian cells and bacteria (Figure 2d). This vector also
contained an origin of replication allowing integration site
analysis based on a plasmid rescue protocol. Stably
expressing SB100X and mSB cells were then infected with
AAV-neo at MOI 1,000 and MOI 10,000. After performing a
colony forming assay including two weeks of selection pressure
we observed 6-fold increased integration efficiencies when
using the SB100X expressing cell line infected with AAV-neo
MOI10,000 (Figure 2d).
To provide SB transposase in a transient manner, HeLa-cells
were transfected with plasmids pCMV-HSB5, pCMV-SB100X
or pCMV-mSB encoding the previously described hyperactive
transposases HSB5 [11], SB100X and the mutated and
inactive transposase mSB. Twenty-four hours post-transfection
all groups were infected with the transposon-donor vector AAV-
neo (Figure 3a). After performing a colony forming assay by
keeping cells under selection pressure for two weeks, we found
that the groups which received the hyperactive SB
transposases SB100X and HSB5 resulted in 10-fold and 2-fold
increased number of colony forming units compared to the
control group which received the plasmid pCMV-mSB (Figure
3b). Due to the low transposition efficiencies of HSB5 in the
context of an AAV vector, we focused our further studies on the
hyperactive SB transposase version SB100X.
Our former studies revealed that predominantly circular DNA
molecules can serve as substrates for transposition [9].
Therefore, we also addressed the question whether
circularization of the transposon-donor as circular monomer
from the various episomal molecular forms of the AAV vector
may increase transposition (Figure S1). To form circular
monomers of the transposon we applied the Flpe/FRT
recombination system for excision of the transposon from the
AAV vector (Figure S1). Towards this end we generated AAV
vector plasmids which after co-transfection can release circular
transposons from the linear AAV genome. In detail, the
transposon-donor plasmid pAAV-neo contains FRT sites
flanking the neomycin encoding transposon (Figure 2d). The
transposase encoding vectors either encode Flpe recombinase
and SB transposase (pAAV-SB100X-Flpe) or solely SB
transposase (pAAV-SB100X) (Figure S2a). We co-transfected
the respective transposon-donor plasmid and one of the
transposase encoding plasmids either with or without a Flpe
encoding sequence. After performing colony forming assays
we found that transposition efficiencies actually decreased in
the presence of Flpe recombinase (Figure S2b). To perform
respective experiments with AAV vectors, we co-transduced
SB100X stably expressing cells (Figure 2) with the transposon
donor vector AAV-neo and the previously described Flp
encoding high-capacity adenoviral vector Ad5-mSB-Flpe [9] to
provide Flpe recombinase in trans. After co-infection, Flp
recombinase first mobilizes the transposon from the AAV
AAV/SB Transposase Hybrid Vector
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genome which can then be integrated into the host genome via
SB-mediated transposition (Figure S1). As shown in Figure S3
transposition efficiency is independent of Flp expression
supplied by Ad5-mSB-Flpe. Based on these studies we
decided to exclude Flpe-mediated excision of the transposon
substrate from the AAV vector DNA molecule.
Transposition efficiencies after co-delivery of the
transposon-donor AAV vector and the transposase
encoding AAV vector
The transposon-donor vector AAV-neo and the vector AAV-
SB100X encoding hyperactive SB transposase under the
control of the cytomegalovirus (CMV) promoter were used to
evaluate transposition efficiencies (Figure 4a). For achieving
somatic integration mediated by SB transposase from the
transposon-donor vector AAV-neo, it is mandatory that cells
are co-infected with both vectors (Figure 1). To optimize
conditions for the AAV/SB transposase hybrid-vector system,
Figure 1.  Principle of the hybrid-vector system based on Sleeping Beauty (SB) transposase-mediated transposition from
AAV vector genomes.  For somatic integration cells were simultaneously infected with the transposon-donor vector and the SB
transposase encoding virus. After entering the cell, single-stranded AAV vector genomes form double-stranded DNA and generate
several different molecular forms including circular monomers, dimers, and concatemers as well as linear monomers and
concatemers [16]. Next, the transposon flanked by inverted repeats (IR, white horizontal arrow) and the AAV-derived inverted
terminal repeats (ITR, black squares) needs to be mobilized from the various AAV vector genome forms. The transposon is then
integrated into the host genome by a cut-and-paste mechanism mediated by the SB transposase protein which is delivered in trans
and encoded by the second vector. Subsequently the transposon is integrated into chromosomal DNA (waved line) into the genomic
target site (TA dinucleotide, grey square).
doi: 10.1371/journal.pone.0076771.g001
AAV/SB Transposase Hybrid Vector
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Figure 2.  Transposition efficiencies in HEK293 cells stably expressing hyperactive Sleeping Beauty transposase
SB100X.  (a) Plasmids pIRES-Puro-SB100X and pIRES-Puro-mSB were generated containing a bicistronic IRES construct
expressing SB100X or mSB and the puromycin resistance gene under the control of the cytomegalovirus promoter (CMV).
(b) Cells were stably transfected with plasmids pIRES-Puro-SB100X or pIRES-Puro-mSB and single cell clones were amplified
under puromycin selection pressure. Total RNA was isolated from single cell clones and RT-PCR was performed to show
expression of SB100X and mSB using primers SB100X-rev and SB100X-forw (Table S1). Clone 3 from the selected SB100X and
mSB cell clones was chosen for further experiments. (+): Cell clones which stably express SB100X or mSB. (-): Cell clones which
were negative for transposase expression.
(c) The previously published plasmid pTnori [10] containing a neomycin encoding transposon was transfected into stably expressing
SB100X and mSB (SB100X-HEK293 and mSB-HEK293) cells and kept under selection pressure using neomycin to select for
transposition events. Obtained cell colonies were stained with methylene blue and counted. Error bars indicate standard deviation
(n=3). *Significant difference between the SB100X and the mSB control groups (p-value < 0.05).
(d) SB100X-HEK293 and mSB-HEK293 cells were infected with the recombinant vector AAV-neo at different MOIs (MOIs 1,000 and
10,000). AAV-neo represents the transposon-donor vector from which the transposon is mobilized. The transposon is flanked by
Sleeping Beauty transposase derived inverted repeats (IR) and it expresses the neomycin resistance gene under control of the
simian virus promoter (SV40) for eukaryotic expression and the Tn5 promoter for expression in bacteria. Additionally the transposon
is flanked by the Flpe recognition sites FRT. Error bars indicate standard deviation (n=3). *Significant difference between the
SB100X and mSB control groups (p-value < 0.05), “n.s.”: not significant, no significant difference between the SB100X and the mSB
control groups (p-value > 0.05).
doi: 10.1371/journal.pone.0076771.g002
AAV/SB Transposase Hybrid Vector
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we co-infected HeLa-cells with viral vectors AAV-neo and AAV-
SB100X using varying MOIs of AAV-neo (MOI 100; MOI 1,000;
MOI 10,000 and MOI 50,000) and AAV-SB100X (MOI 1,000;
MOI 10,000 and MOI 50,000). Colony forming assays were
performed and stable cell clones were quantified and analyzed
on a molecular level with respect to vector genome copy
numbers and integration sites within the host genome. A
schematic outline of the procedure is shown in Figure 4b.
Highest numbers of colonies were obtained after co-infection
with AAV-neo at MOI 10,000 and AAV-SB100X at MOI 10,000
(Figure 4c). As a control, other groups received the control
vector AAV-mSB expressing an inactive version of the SB
transposase (mSB) (Figure 4a) at varying MOIs (MOI 1,000;
MOI 10,000 and MOI 50,000) along with the vector AAV-neo at
MOI 1,000 and MOI 10,000. This experimental setup resulted
in more than 10-fold decreased numbers of resistant cell
clones in all mSB control groups (data not shown).
Figure 3.  Transposition efficiency after infection with the transposon-donor vector AAV-neo co-transfected with
transposase encoding plasmids.  (a) Colony forming assay to determine integration efficiencies from the AAV-neo vector co-
transfected with transposase encoding plasmids. HeLa-cells were first transfected with 1µg of the respective transposase encoding
plasmid (pCMV-mSB, pCMV-HSB5, or pCMV-SB100X) and one day post-transfection cells were infected with AAV-neo at MOI
10,000. Two days post-infection cells were diluted and kept under selection pressure for 14 days. Obtained cell colonies were either
collected as cell pools for integration site analysis or stained with methylene blue to determine transposition rates. Transposase
encoding plasmids contain expression cassettes for the hyperactive transposases HSB5 and SB100X and the inactive SB
transposase version mSB expressed under the control of the cytomegalovirus promoter (CMV).
(b) Result of the colony forming assay. The Y-axis shows the number of neomycin resistant colonies obtained from 4 x 105 cells in
different experimental settings. The lower panel shows examples of original tissue culture plates from the different groups after
methylene blue staining. Error bars indicate standard deviation (n=3). *Significant difference between the hyperactive transposase
groups (SB100X and HSB5) and the mSB control group (p-value < 0.05).
doi: 10.1371/journal.pone.0076771.g003
AAV/SB Transposase Hybrid Vector
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Molecular analysis of transposition events
To perform molecular analysis of AAV transduced cells, we
determined DNA copy numbers of several components
essential for the AAV/transposase hybrid-vector system by
quantitative real-time-PCR (qRT-PCR). This PCR analysis
included quantification of the neomycin resistance gene, the
AAV ITR and the transposase encoding DNA (Figure 5a). The
Neo-PCR (Figure 5a, upper panel) detected the neomycin
encoding gene which included three potential molecular forms,
comprising the transposon that is derived from SB-mediated
integrations, the transposon derived from the original AAV-neo
viral vector genome integrated into the host genome by AAV-
vector mediated integration, and potential remaining episomal
AAV vector genomes carrying the neo transgene. We detected
>1 copies per cell of the neomycin gene in four groups which
received a high dose of the AAV-neo vector (MOIs 10,000 and
50,000) along with a high dose of the vector AAV-SB100X
(MOIs 10,000 and 50,000) (Figure 5b). Notably, highest
neomycin copy numbers (2,500 neomycin copies/1,000 cells)
were detected in cells which were co-infected with both vectors
at MOI 10,000 (Figure 5b). The SB-PCR (Figure 5a, middle
panel) detects the SB transposase genes (SB100X and mSB).
These stably maintained SB encoding DNAs are most likely
Figure 4.  Transposition efficiency of the AAV/SB transposase hybrid-vector system.  Colony forming assay to determine
integration efficiencies from the hybrid AAV/SB vector system in HeLa-cells. HeLa-cells were co-infected with AAV-neo and AAV-
SB100X at increasing dosages (MOI 100, 1,000, 10,000 and 50,000).
(a) The AAV vector AAV-SB100X contains a transgene expression cassette for the hyperactive Sleeping Beauty (SB) transposases
SB100X expressed under the control of the cytomegalovirus promoter (CMV). The control vector AAV-mSB encodes the mutated
and inactive version of SB (mSB).
(b) After co-transduction and selection, obtained cell colonies were either collected as pools for integration site analyses or colonies
were stained with methylene blue and counted to determine integration efficiencies.
(c) Result of the colony forming assay. The Y-axis shows the number of neomycin-resistant colonies obtained in different
experimental settings. Error bars indicate standard deviation (n=3). n.d.: not determined.
doi: 10.1371/journal.pone.0076771.g004
AAV/SB Transposase Hybrid Vector
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due to AAV-vector mediated integration of AAV vectors AAV-
SB100X or AAV-mSB. The SB transposase copy numbers
revealed that less than <1 copy per cell (10 SB copies/1000
cells) were maintained in most groups, except for the two
groups which received a high dose of AAV-neo (MOI 10,000
and 50,000) and MOI 50,000 of AAV-SB100X (Figure 5c). The
AAV-ITR PCR measures total AAV viral genome copy numbers
directly matching the number of AAV vector DNA molecules in
transduced cells (Figure 5a, lower panel). We detected AAV-
SB100X dose-dependent effects on ITR copy numbers in cells
which were co-infected with AAV-neo at MOI 100, MOI 10,000,
MOI 50,000 (Figure 5d).
Next we wanted to analyze the integration profile of our AAV/
transposase hybrid-vector system. As controls for integration
site analysis in the absence of transposase, we performed
colony forming assays utilizing the inactive and mutated
version of SB transposase (mSB). However, we did not
perform colony forming assays for all possible vector
Figure 5.  Genome copy numbers of each hybrid-vector element after AAV transduction.  Genomic DNA of neomycin-
resistant cells (from Figure 4) was analysed by quantitative real-time PCR (qRT-PCR) using primers and probe detecting AAV-ITRs
and primers detecting the cDNAs of the two main functional genes neo (neomycin resistance gene) and SB (Sleeping Beauty
transposase encoding gene). As internal control a PCR detecting hB2M (Beta-2-microgloblin gene) was performed.
(a) PCR setup and location of primers used for quantitative analysis of vector genome copy numbers. The neo-PCR detects a 337
bp region in the neomycin resistance gene, which include integrated transposon, non- integrated and integrated AAV genomes. The
SB-PCR detects an 82 bp region contained in the SB transposase encoding gene. Primers and probe specifically detecting the AAV
ITR region [44] were used for amplification and detection of a 62 bp PCR product. Red arrows depict real-time PCR primer binding
sites.
(b) Neomycin copy numbers per 1000 cells after AAV transduction. Error bars indicate standard deviation (n=3).
(c) SB transposase copy numbers per 1000 cells. Error bars indicate standard deviation (n=3).
(d) 2XITR copy numbers per 1000 cells in co-transduced cells. Error bars indicate standard deviation (n=3).
doi: 10.1371/journal.pone.0076771.g005
AAV/SB Transposase Hybrid Vector
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combinations and ratios as shown in Figure 4c. We only
analyzed the AAV-neo vector at MOI 1,000 and MOI 10,000 in
combination with the AAV-mSB vector at MOI 1,000 and MOI
10,000, and MOI 50,000 (Table S2), because these MOIs also
gave the best results when using the hyperactive Sleeping
Beauty transposase SB100X (Figure 4c). For detailed
characterization of transposition events on a molecular level,
we identified integration sites using a strategy based on
plasmid rescue (Figure 6a) and a linear amplification-mediated
PCR (LAM-PCR) protocol (Figure 6b). The plasmid rescue
method allows differentiating between actual transposition
events from the AAV vector genome and integration of the
complete AAV genome due to AAV-vector mediated integration
because sequences flanking both ends of the AAV vector
genome can be determined. If AAV-vector mediated integration
occurs, rescued AAV-vector mediated integration events
should still carry the AAV-derived ITRs and the inverted
repeats (IRs) from the transposon, while rescued transposition
events should solely contain SB transposon IRs. Towards this
end we analyzed genomic DNA from cells which were co-
infected with AAV-neo and AAV-SB100X at MOI 10,000 for
both recombinant viruses. We isolated a total of 99 integration
events of which 96 events were identified as transposition
events and three events were AAV-vector mediated integration
events (Table 1). From the other groups which received
different MOIs, we rescued 13 transposition events. For the
mSB group 7 integration events were identified of which four
were AAV-vector mediated integration events (Table 1 and
Table S2). Compared to a random chromosomal distribution,
chromosomal distribution of transposition events after infection
with the AAV/transposase hybrid-vector system revealed a
slight bias towards transposition into chromosomes 1 and 5
(Figure 6a). Using the LAM-PCR method we identified a total of
1716 transposition events (1622 for sample 1 and 94 for
sample 2) which were characterized on a molecular level. In
concordance with the plasmid rescue protocol we observed a
slight integration bias towards chromosome 1 and 5 for sample
1 (AAV-neo MOI 10,000 and AAV-SB100X MOI 10,000) in the
LAM-PCR analysis. For the second sample (AAV-neo MOI
10,000 and AAV-SB100X MOI 50,000) there was a slight bias
towards integration into chromosomes 5 and 17. A summary of
all integration sites obtained by plasmid rescue and LAM-PCR
is provided in Table 1 and Figure 6.
To evaluate genotoxicity of the AAV/transposase hybrid-
vector system we analyzed whether transposons landed in
gene or non-gene areas. Interestingly, for the plasmid rescue
method 49% percentage of integration sites were identified to
be intragenic (Figure 7a, left panel). Among these intragenic
integrations only 3 were in exons and the remaining
transposition events were found to be located in introns (53,
95%). Most intergenic integrations were found to be far away
from genes (94% locate >10 kb away) (Figure 7a, right panel).
For the LAM-PCR method we observed a random integration
pattern with respect to integration into intra- and intergenic
regions (Figure 7b, left panel). Also, the distance of integration
in close proximity to genes was not changed significantly
compared to a random integration profile (Figure 7b, right
panel).
To estimate to which extent SB transposase-mediated
transposition contributes to stabilization of the transgene after
transduction of cells with AAV vectors, we performed a
calculation based on the qRT-PCR data (Figure 5). We found
that the percentage of SB-mediated integration depends on the
MOI of both transposase and transposon-donor vectors (Figure
8a). In those groups which received the lowest dose of the
vector AAV-neo (MOI 100), SB-mediated integration events
corresponded only to 50% of all integration events containing
the neomycin transgene. For the group which received AAV-
neo and AAV-SB100X at MOIs 10,000, showing highest
numbers of colonies in the colony forming assay (Figure 4c),
98% of all stabilized neomycin transgene copies were from SB-
mediated integrations. The vector dose-effect on transposition
efficiencies and potential AAV-vector mediated integrations
from the AAV/transposase hybrid-vector is schematically
shown in Figure 8b.
Discussion
AAV vectors are broadly used in clinical applications and
therefore this type of vector holds great promise for gene
therapeutic applications [2,4]. However, in cycling and
regenerating tissues the genetic payload gets lost rapidly [7]
because of the lack of a stabilizing genetic element during
mitosis. Herein, we developed the first prototype of a
recombinant AAV vector which utilizes the SB transposase
somatic integration machinery for stabilized transgene
expression in combination with the high transduction
efficiencies of AAV.
We first assessed whether excision of the transposon from
the various molecular forms of the AAV vector genome [16]
after cellular transduction is required. We found that Flpe
mediated excision and circularization of the transposon from
the AAV vector genomes is not mandatory (Figures S2 and
S3). After AAV transduction circular monomers and
concatemers and linear integrated and non-integrated vector
DNA molecules are produced [16] and these seem sufficient to
serve as substrates for transposition (Figure 1). In fact, Flpe
recombination seems to decrease transposition efficiencies in a
plasmid based context (Figure S2b) which may be caused by
the fact that Flpe recombination [17] represents a bidirectional
reaction. FRT recombination events between integrated and
episomal AAV vector forms may occur which could interfere
with the transposition reaction. This finding is important for the
molecular design of the AAV/transposase hybrid-vector
system, because FRT sites and Flpe encoding sequences can
be deleted from the AAV-hybrid vector system, significantly
simplifying the molecular setup. This feature of the AAV/
transposase hybrid-vector system may be advantageous
compared to the previously published adenovirus/transposase
hybrid-vector system [9,18] for which Flpe mediated excision of
the transposon from the adenovirus vector genome is required.
Notably, Flpe expression seems to have different effects on
colony forming numbers dependent on whether the Flpe
transgene was introduced into target cells by plasmid
transfection or by an adenoviral vector infection (Figure S2 and
Figure S3). However, in contrast to experiments shown in
AAV/SB Transposase Hybrid Vector
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Figure S2, the adenovirus experiments were performed in the
stably expressing SB100X cell line which means that SB100X
was already expressed before Flpe was introduced. As a
consequence Flpe may have less pronounced effects on the
outcome of the experiment. As a second point, it should be
mentioned that in contrast to plasmid transfection, adenovirus
infection results in significantly decreased copy numbers of the
Flpe transgene and its translated protein. This in turn may lead
to enhanced Flpe effects in cells which received the Flpe
transgene based on plasmid transfection.
We tested and compared two different hyperactive SB
transposase versions (HSB5 and SB100X) and found that in
the context of an AAV vector SB100X and HSB5 showed 10-
fold and 2-fold increased activity compared to the mSB control
group (Figure 3). Therefore, we pursued our further
experiments with the hyperactive Sleeping Beauty transposase
SB100X. A previously published lentivirus-transposase hybrid-
vector utilized hyperactive SB transposases SB100X, SB80X
and HSB3 (a progenitor of HSB5) for somatic integration from
an integrase-deficient lentiviral vector (IDLV) [19]. Also in this
study SB100X but also SB80X were superior to HSB3 with
Figure 6.  Integration sites from the hybrid AAV/SB vector system identified by plasmid rescue and LAM-PCR
approaches.  (a) Integration events identified by plasmid rescue. Percentages of integration events within each individual
chromosome in comparison to a random control set is depicted in the upper panel. A schematic overview of chromosomal
distribution is shown in the lower panel. The relative position of all unique integration sites identified from AAV/SB hybrid vector
system infected cells were mapped within the human genome. Respective triangles indicate the relative positions of the
chromosomal integration site observed (red triangle for SB-mediated integration; blue triangles for AAV -mediated integration).
(b) Sequence reads and chromosomal distribution identified after performing LAM-PCR in AAV/SB hybrid-vector infected HeLa-cells
(upper panel). Integration sites were compared to a computer-simulated random integration profile [13]. The lower panel shows
mapping of all 1716 unique integration sites identified by LAM-PCR. Respective triangles indicate the relative positions of the
chromosomal transposon integration site observed from sample 1 (blue triangles, AAV-neo MOI 10,000 and AAV-SB100X MOI
10,000) and sample 2 (red triangles, AAV-neo MOI 10,000 and AAV-SB100X MOI 50,000).
doi: 10.1371/journal.pone.0076771.g006
AAV/SB Transposase Hybrid Vector
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respect to transposition efficiencies. Another study applied
hyperactive SB transposase SB11 displaying 3-fold increased
transposition activity compared to wild type SB transposase
(SB10), but the respective transposition efficiencies not
compared to other hyperactive or inactive SB transposase
versions [15]. However, in contrast to studies using IDLV for
transposon delivery, AAV vector integration itself is
unavoidable for our AAV/transposase hybrid-vector. However,
somatic integration efficiencies of recombinant AAV vectors are
rather low [7], which is also in concordance with the findings of
the present study.
In contrast to experiments involving AAV transduction
(Figure 2 and Figure 3), we observed approximately 100-fold
increased transposition activities when using plasmids as
transposon-donor and transposase encoding vector (Figure 2
and Figure S2). However, for plasmids transfection efficiencies
are usually high and hundreds of plasmid copies will co-
transfect target cells. In contrast, if one component of the SB
transposase system or both transposon-donor and transposase
encoding vector are delivered by an AAV vector, transduction
efficiencies are significantly lower compared to plasmid
transfection. This is mainly due to the fact that in general AAV
transduction efficiencies in immortalized cells in vitro are lower
than with plasmid transfection. One could also speculate that
plasmids entering the target cell already as a circular DNA
genome are more efficient in serving as substrates for
transposition than AAV vectors which enter the cell as single-
stranded DNA genomes which are subsequently converted into
double-stranded DNA. This was also the reason for generating
stably transposase-expressing cell lines in our initial study
(Figure 2a and b), because this strategy would bypass second-
strand synthesis and the transcription and translation steps of
the transposase. Although it seems that for the used cell clones
(clone 3 for SB100X and clone 3 mSB) there are higher
expression levels of SB100X compared to mSB (Figure 2b), it
is of note that SB100X and mSB transposase transcription was
detected by regular reverse transcription PCR and that we did
not quantify transcription levels. Nevertheless, in the stable cell
lines it may also be possible that there are different integrated
vector genome copy numbers of SB100X and mSB transgenes
inserted into the host genome and thereby also different
expression levels. However, we believe that this should not
significantly influence final transposition efficiencies. If there is
more mSB, anyhow the mSB is inactive for transposition. In
case there is too much SB100X expressed in this cell line, we
believe that it is unlikely it may increase transposition activities.
The main effect, overexpression of SB100X may have on the
cells, may be over-production inhibition or SB transposase
mediated cytotoxicity. It is of note that not only the vector
genome copy numbers of the integrated plasmid may influence
SB100X and mSB expression levels, but also the locus in the
host chromosomes into which the plasmid integrated.
With respect to the integration profile analyzed by LAM-PCR
and plasmid rescue we found a close to random integration
pattern with a moderate bias towards integration into
chromosome 5 for both methods and all analyzed samples
(Figure 6). Therefore, we concluded that the integration pattern
mainly mimicked transposition events observed in non-viral
approaches and for the IDLV/SB transposase hybrid-vector
system [13-15,19]. Slightly enhanced integration into
chromosome 1 (Figure 6) may be explained by the fact that
chromosome 1 represents the largest chromosome in the
human genome. In addition, it could be speculated that
analyzing more integration sites may decrease the marginal
bias towards certain chromosomes which was also observed in
other studies [13-15,19]. With respect to integration into genes
and non-gene areas we found that for the plasmid rescue
method up to 49% of the integration events landed in genes
and for the LAM-PCR we observed a close to random
distribution of transposition events (Figure 7). Compared to
other studies this transposon integration profile is similar to the
one observed in other studies for which SB transposase-
mediated integration efficiencies into genes varied form
39-53% [13-15,19]. It is of note that for conventionally used
recombinant AAV vectors integration efficiencies into gene
Table 1. AAV- and SB-mediated integrations and number of rescued plasmids from each group.
AAV-neo MOI 100 MOI 1,000 MOI 10,000 MOI 50,000
 % SB IS PR IS LP % SB IS PR IS LP % SB IS PR IS LP % SB IS PR IS LP
AAV-SB100X
MOI 1,000 47.4 0/0 n.d. 66.0 1/0 n.d. 88.6 6/0 n.d. 90.4 0/0 n.d.
MOI 10,000 50.3 0/0 n.d. 92.1 2/0 n.d. 98.5 96/3 1622 98.2 2/0 94
MOI 50,000 51.4 2/0 n.d. 66.8 0/0 n.d. 78.7 0/0 n.d. 72.7 0/0 n.d.
AAV-mSB
MOI 1,000 n.p. n.p.   0/0 n.d.  0/2 n.d. n.p. n.p.  
MOI 10,000 n.p. n.p.   1/1 n.d.  2/0 n.d. n.p. n.p.  
MOI 50,000 n.p. n.p.   0/1 n.d.  0/0 n.d. n.p. n.p.  
% SB: provides the percentage of SB transposase-mediated integration events in all analysed integration sites calculated by the gene copy number measured by
quantitative real-time PCR (see also Figure 8). IS PR: provides the number of rescued transposition events and the AAV-vector mediated integration events (No. of
transposition events/ No. of AAV vector integration events). IS LP: provides the number of rescued transposition events using LAM-PCR. Vector combinations which were
not performed are noted as n.p. 0/0: >20 colonies were picked for analyses but no transposition events and/or AAV-vector integration events were rescued. n.d.: not
determined.
doi: 10.1371/journal.pone.0076771.t001
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regions range from 39% [20] to 53% [21] in vitro and reach up
to 61% in vivo [21].
We analyzed the relation between transgene stabilization
and AAV vector dosages used for cell transduction.
Determined genome copy numbers of the transposon encoding
neomycin, the SB transposase and the AAV-ITR, together with
the identified integrations gave basic information about the
AAV-transposase hybrid-vector system. We found that
transgene stabilization due to SB transposase-mediated
integration was vector dose-dependent (Figures 4, 5, 8 and
Table 1). As shown in Figure 5b, in four groups which received
high vector dosages (MOIs 10,000 and 50,000), >1 copy/cell of
the neomycin gene was detected indicating that more than a
single integration event occurred per single cell. Moreover, we
observed a relatively high amount of transposase genome copy
numbers compared to the mSB control group (Figure 5c and
Table S2). At the time we can only speculate about the reasons
responsible for this phenomenon. We used a high dose of the
AAV-SB100X vector and since one of the intrinsic properties of
SB transposase is introducing double-strand breaks into the
genome, random integration frequencies may be increased.
Another possibility could be that the transposase encoding
sequence retained some residual transposon activity which
could result in increased somatic integration in groups which
received the hyperactive transposase SB100X. A previous
study by Huang and colleagues [22] also detected high copy
Figure 7.  Frequencies of insertions from hybrid AAV/SB vector system within or outside of genes.  (a) Characterization of
AAV/transposase hybrid-vectors mediated integrations identified by plasmid rescue. Percentage of integration sites which were
identified to be intragenic (in introns, or in exons) and intergenic after performing plasmid rescue (left panel). Random: computer
predicted data [13]. The right panel shows the distance to the nearest genes of integration sites which hit intergenic regions.
Distances of genes upstream and downstream of the transposition event are depicted.
(b) Characterization of AAV/transposase hybrid-vectors mediated integrations identified by LAM-PCR method. Insertion frequencies
compared to a random dataset are shown with respect to integration within and outside of RefSeq genes (left panel), and distances
upstream and downstream of genes (right panel). The bars depict fold changes of integration frequencies compared to the random
distribution profile. Abbreviation: sample 1 (AAV-neo MOI 10,000 and AAV-SB100X MOI 10,000) and sample 2 (AAV-neo MOI
10,000 and AAV-SB100X MOI 50,000).
doi: 10.1371/journal.pone.0076771.g007
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numbers of integrated transposase transgenes in transduced
cells. However, compared to our study integration efficiencies
in the presence of inactive SB transposase proteins were not
analyzed. With respect to safety, somatic integration and
subsequent long-term SB transposase expression in
transduced cells may harbor the risk for unwanted side effects
such as secondary transposition. However, the work by Huang
and colleagues and another study by Bell and colleagues [23]
indicated that the maintained SB transposase encoding
transgenes are silenced over time, lowering the risk of
unwanted side effects.
We found that AAV-vector mediated integration occurs not
only in the mSB groups but also in the groups which received
SB100X (Table 1). As AAV seems to have a strong preference
for integrating near gene regulatory sequences and
transcriptional start sites [21], it is important to study how to
control and restrain AAV-vector mediated integrations while
maintaining high transduction and transposition efficiencies.
Towards this end, we aimed at analyzing SB-mediated
transposition efficiencies in relation to AAV vector integration
which is schematically shown in Figure 8. Notably, when using
an MOI of 50,000 for both vectors, we observed a decrease of
transposition efficiencies which may be due to an over-
production effect [24,25]. Furthermore, increasing the MOI of
AAV-SB100X led to decreased numbers of colony forming
units compared to the MOI 10,000 to MOI 10,000 ratio of AAV-
neo and AAV-SB100X, respectively (Figure 4). The effect may
be due to the fact that an increased number of AAV vector
genomes encoding SB100X may integrate into the host
genome potentially resulting into toxicity due to stable
expression of the hyperactive transposase gene.
Figure 8.  Transposition efficiencies are dose-dependent.  (a) To calculate the ratio of SB transposase-mediated integration
versus AAV-vector mediated integration, the percentage of SB-mediated integration events contained in all integration events (SB-
mediated integration events + AAV-vector mediated integration events) was determined. Calculation: (neomycin gene copy number
determined by qRT-PCR) – [(AAV-ITR copy number determined by qRT-PCR) – (SB copy number determined by qRT-PCR)] /
(neomycin gene copy number determined by qRT-PCR) x 100. It is of note that the low percentage of potentially remaining non-
integrated AAV vector genomes should also be detected by the neomycin-specific primers.
(b) Schematic overview of dose-dependent transposition efficiencies. The X-axis indicates increased dosages of the transposase
encoding vector AAV-SB100X while the Y-axis indicates the increase of the AAV-neo vector. The dashed red arrow represents the
trend of AAV-vector mediated integrations and the blue curve displays the efficiency of SB-mediated integrations in a dose-
dependent manner.
doi: 10.1371/journal.pone.0076771.g008
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Another interesting finding can be derived from the groups
which received the transposon-donor vector (AAV-neo) and the
inactive version of transposase mSB (AAV-mSB). In contrast to
the active transposase groups, genome copies of neomycin
and AAV-ITR sequence copy numbers showed relatively high
levels (Table S2). For instance, a similar level of neomycin and
AAV-ITR copy numbers (~ 300 copies/1000 cells) was detected
in the group which received AAV-mSB at MOI 50,000 and
AAV-neo at MOI 1,000. This underlines that integration events
are mainly AAV-vector derived. However, we identified a very
limited number of SB-mediated integrations from groups which
received mSB (Table 1), which may be explainable by the fact
that mSB displays residual transposase activity.
Our AAV/transposase hybrid-vector system represents the
first prototype of an AAV vector capable of maintaining
transgene expression even during rapid cell cycling. Hybrid-
vector technologies were also used for adenoviral vectors,
herpes-simplex virus based vectors and the integrase-deficient
non-integrating lentivirus technology [26-32]. For these hybrid-
vector systems various genetic elements for retention and
replication of the therapeutic DNA after cellular transduction
were evaluated. These genetic elements included
bacteriophage derived integrase PhiC31 for somatic integration
into genomic hot spots [33], zinc finger nucleases (ZFNs) and
transcription activator like elements (TALEN) [34-36] for gene
insertion at pre-determined genomic loci, retrotransposons
from somatic integration [37], AAV Rep protein for site-specific
integration in chromosome 19 [38], and genetic elements such
as S/MAR based vectors [39] and Epstein-Barr virus based
vectors [40,41] for episomal maintenance of the transgene. In
the future, AAV may also be combined with other genetic
elements for stabilized transgenes expression besides the SB
transposase system.
In summary, we show for the first time that AAV vectors can
serve as template for SB transposase-mediated somatic
integration. With further improvements regarding SB
transposase-mediated integration efficiencies from the AAV
vector genome and AAV-transduction efficiencies, this vector
system can pave the way towards treatment of diseases which
require stable gene transfer into rapidly dividing cells.
Materials and Methods
Cell lines
HeLa-cells (human cervical cancer cells) and human
embryonic kidney cells (HEK293-cells) were cultured in
Dulbecco’s modified Eagle’s medium (DMEM, PAA)
supplemented with 10% fetal calf serum. All cell lines were
cultured at 37 °C in a 5% humidified atmosphere.
Transposase stably expressing HEK293-cells were
generated by stably transfecting plasmids pIRES-Puro-SB100X
or pIRES-Puro-mSB. Single cell clones were amplified under
puromycin selection pressure and tested for SB transposase
expression using reverse-transcription PCR.
Colony forming assays
For colony forming assays solely based on plasmid
transfection, HeLa-cells were seeded in 6-well plates at a
density of 3 × 105 cells/well in 3 ml medium. Transfection was
carried out the next day in serum-free medium with FuGENE 6
(Promega) according to manufacturer’s protocol. A total of 2 µg
of plasmid DNA with molar ratio of 1:2 between transposase–
encoding plasmid and transposon substrate plasmid was
transfected using a FuGENE-to-plasmid ratio of 3:2. After 2
days, the transfected cells were trypsinized and reseeded in
10-cm dishes at different dilutions. Two days later the cells
were selected in Geneticin-containing medium (500 µg/ml
G418) for 14 days. Drug-resistant colonies were either stained
with methylene blue (Sigma-Aldrich) and counted or collected
as cell pools for integration site analysis.
For colony forming assays based on plasmid transfection
and subsequent AAV infection, HeLa-cells cultured in 6-well
plates were first transfected with 1µg (100,000 copies per cell)
of the respective transposase encoding plasmid (pCMV-mSB,
pCMV-HSB5, or pCMV-SB100X). One day post-transfection
cells were infected with the vector AAV-neo at MOI 10,000.
Two days post-infection cells were harvested and seeded using
cell densities of 4x105 cells per 10-cm dish. After 14 days under
selection pressure, cell colonies were either collected as pools
for integration site analysis or the colonies were stained with
methylene blue and counted to determine transposition
efficiencies.
When performing colony forming assays relying on co-
infection with the transposase encoding vector AAV-SB100X
and the transposon-donor vector AAV-neo, HeLa-cells at
50-80% confluency grown in 6-well plates were co-infected with
AAV-neo and AAV-SB100X at increasing dosages (MOI 100,
1,000, 10,000 and 50,000). Two days post-infection cells were
harvested and seeded at cell densities of 4x105 cells per 10-cm
dish. After 14 days under selection pressure, surviving cells
were either collected as pools for integration site analysis or
the colonies were stained with methylene blue and counted to
determine transposition efficiencies.
All plasmid transfection and viral vector infection were
performed in triplicate.
Cloning of recombinant AAV vectors
To clone the AAV production plasmid pAAV-neo, the plasmid
pZac2.1 (obtained from Jim Wilson, University of Pennsylvania,
Philadelphia, PA, USA) containing the AAV ITRs was cut with
the restriction enzyme SnaBI and the blunted I-CeuI/PI-SceI
fragment from pHM5-attB-TMCS-FRT2 [18] was ligated into that
side resulting into the plasmid pZAC- attB-TMCS-FRT2. To clone
the AAV production plasmid pAAV-neo, we cloned the EcoRI
fragment from the plasmid p11 with the neomycin resistance
gene [42] into the PmeI site of pZAC- attB-TMCS-FRT2.
Plasmids pCMV-HSB5, pCMV-mSB and pCMV-SB100X and
the FLPe encoding plasmids used as PCR templates were
published previously [9,10,33] To clone AAV production
plasmids pZIF-SB100X-Flp, pZIF-HSB5-Flp, pZIF-mSB-Flp we
PCR amplified the IRES sequence (619 bp) from the
pIRESpuro vector (Clontech) using primers IRES-forw-XbaI/
BclI and pIRES-rev- XbaI/BamHI. Furthermore, we amplified
the Flpe gene (1300 bp) using primers Flpe-forw-BamHI and
Flpe-rev-NotI and the SB transposase gene (1022 bp) using
template plasmids pCMV-HSB5, pCMV-mSB and pCMV-
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SB100X and primers SB-forw-XhoI and SB-rev-EcoRI.
Resulting PCR products were cloned into the respective sites
of the AAV cloning vector pZac2.1. To clone vectors pZAC-
SB100X, pZAC-HSB5 and pZAC-mSB DNA sequences were
PCR amplified using the same primers and cloned into the
XhoI and EcoRI sites of the plasmid pZac2.1. For detailed
description of each primer pair please refer to Table S1.
AAV production and titration
Recombinant AAV vectors were generated utilizing calcium
phosphate mediated triple transfection of HEK293-cells [43].
Recombinant AAV vector genomes were packaged into
capsids from AAV-2 using the helper plasmid pRC (gift from
Hildegard Büning, University of Cologne, Cologne, Germany)
and the adenoviral helper plasmid pAdDeltaF6 (obtained from
Jim Wilson, University of Pennsylvania, Philadelphia, PA,
USA). For final AAV production, plasmids containing the gene
of interest need to be packaged into AAV virions, we used
plasmid pAAV-neo (containing the neomycin resistance gene)
and plasmids pZAC-SB100X and pZAC-mSB (containing
transgene expression cassettes for the hyperactive Sleeping
Beauty transposase SB100X and the mutated and inactive
version mSB, respectively). For triple-transfection of the two
helper plasmids and the transgene encoding AAV vector
genome, 35 µg of plasmid DNA (mixed in equimolar ratios) was
used per 15 cm cell tissue culture plate. Three days after
transfection, AAV vectors were harvested. For purification, the
ViraBind™ AAV Purification Mega Kit (Cell Biolabs) was used
according to the manufacturer’s instructions.
SB100X and mSB reverse transcription PCR to analyse
expression in stably transduced cells
The RNA of 3.2x106 cells was isolated using the RNeasy kit
(Qiagen) following the manufacturer instructions. After
determining the RNA amount by measuring the optical density,
1 µg RNA was used for reverse transcription using polydT
primer supplied in the First strand DNA synthesis kit (NEB).
The generated cDNA was then subjected to a PCR reaction
with SB100X and mSB specific primers SB100-for and SB100-
rev (Table S1).
Quantification of vector genome copies by quantitative
real-time PCR (qRT-PCR)
For the quantification of the major genes (neo and SB) from
each vector, qRT-PCR with the primer pairs specific for the
respective gene sequences were performed using the CFX96
Touch™ Real-Time PCR Detection System (Bio-Rad). The
PCR was carried out with the following program: pre-
incubation/activation at 95°C for 5 min, amplification and data
collection during 40 cycles (95°C for 15 s and 60°C for 1 min),
and subsequent melt curve analysis from 55 to 95 °C. iQ™
SYBR® Green Supermix (Bio-Rad) was used for the PCR
setup.
A primer pair and probe [44] binding to the ITR sequence of
AAV was used to determine the copy number of AAV vector
genomes in transduced cells. The PCR was based on the
following program: pre-incubation/activation at 95°C for 5 min,
amplification and data collection during 40 cycles (95°C for 15
s and 60°C for 30 s). The Sso Fast™ Probes Supermix (Bio-
Rad) was used for these PCRs.
To normalize the different samples, the same amount of
genomic DNA was analyzed by real-time PCR detecting the
human B2M gene (Beta-2-microgloblin). For detailed
description of each primer pair please refer to Table S1.
In the quantitative PCR all standards and samples were
performed in triplicate.
Mapping of integration sites
Integration sites were rescued from AAV/SB-transduced cells
by plasmid rescue method as previously described [42]. Briefly,
genomic DNA isolated from selected geneticin-resistant cell
clones was first digested with restriction enzymes NheI, SpeI
and XbaI producing compatible ends (5’ CTAG). Importantly,
these restriction enzyme recognition sites are not present in the
integrated transgene expression cassette. The genomic DNA
fragments were subsequently self-ligated to generate plasmids,
which contain a neomycin resistance transgene and a bacterial
origin of replication, which are both included in the transposon,
and the respective genomic DNA fragment of the integration
sites. After transformation into DH10B competent cells, single
bacterial colonies were amplified and respective DNA of
plasmids was purified. These plasmids were pre-screened by
HindIII restricted enzyme, which releases a 2.5-kb band from
the integrated transgene. Only plasmids contained the 2.5 kb
fragment after HindIII digest and a unique DNA segment larger
than 200 bp were sequenced utilizing the primers binding to the
left IR (L-IR) or the right IR (R-IR). Sequences flanking the IRs
contained genomic DNA sequences connected by the trail of
the restriction enzymes (RE) at the end which were used for
restriction enzyme digests of genomic DNA.
The generation of Sleeping Beauty transposase-mediated
integration site libraries via LAM-PCR in combination with an
Illumina Genome Analyzer platform was performed as
described previously [14,19,45]. Briefly, three enzymes NlaIII
(NEB), MluCI (NEB), FspBI (Fermentas) were used to prepare
independent reactions for LAM-PCR.
Bioinformatic analysis of integration sites
Sequences were blasted against the human genomic
sequence database from NCBI (http://www.ncbi.nlm.nih.gov/
genome/seq/BlastGen/BlastGen.cgi?taxid=9606). Integration
events were considered authentic only if they (1) contained the
sequence from the sequencing primer until the end of the
inverted-repeat (IR), (2) matched a genomic location starting
immediately after the end of IR (TCAACTG) and starting with a
TA-dinucleotide sequence, (3) showed >95% identity to the
genomic sequence, and (4) matched no more than one
genomic locus with the highest identity. Only sequences
combining all these four features were used for further
analyses. For the identification of AAV vector-mediated
integrations, the genomic locations need to start after the AAV
ITR.
For LAM-PCR only the reads with exact adaptor sequence
(23nt) were retained for subsequent analysis. The remaining
part of the single reads containing putative genomic sequences
were cut after 50nt. We mapped these reads to genome while
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only the sites with TA nucleotides were accepted. It is of note,
that for the LAM-PCR dataset, AAV-vector mediated integration
events were neglected. To map the individual integration
events in human chromosomal DNA, the program Bowtie was
used. To improve the data quality, we discarded all sequences
for which we obtained <5 reads. To map these integrations
identified by LAM-PCR back to individual chromosomal DNA,
the Ensembl genome browser was used (the GRCh37.p10
Primary Assembly of the human genome). For statistical
analysis, we used random control sets with 10,000 sites each
as described previously [14,19,45].
Statistical analysis
All experiments in this study were performed in triplicate. All
data are reported as mean with standard deviation unless
otherwise noted. Statistical comparison was made using the
two- tailed student’s test, and a value of p < 0.05 was
considered to be relevant compared to the respective control
group.
Supporting Information
Figure S1.  Molecular design of the AAV/SB hybrid vector
system. For somatic integration cells are simultaneously
infected with the transposase-vector and the transposon donor
vector. After entering the cell, AAV vector genomes form
different molecular forms including circular monomers, dimers,
and concatemers as well as linear monomers and
concatemers. Two strategies were pursued to mobilize the
transposon form the AAV vector representing the transposon-
donor: (I) the transposon flanked by inverted repeats (IR, white
horizontal arrows) is directly mobilized from the AAV vector
genome by the SB transposase protein provided in trans, and
integrated into a genomic target site (TA dinucleotide) (II). After
entering the cell, Flpe recombination excises and circularizes
the transposon from the various forms of the AAV vector
genomes by recognizing the FRT sites contained in the
transposon donor vector. Subsequently, the transposon flanked
by IRs is mobilized from the circular intermediate by the SB
transposase protein provided in trans. As a last step the
transposon integrates in the host genome (waved black lines)
into the genomic target site (TA-dinucleotide).
(TIFF)
Figure S2.  The effect of Flpe expression on transposition
efficiencies. Colony forming assays were performed in HeLa-
cells. (a) The Sleeping Beauty transposase encoding AAV
plasmids pAAV-SB100X, pAAV-SB100X-Flpe, express
transposase under the control of the cytomegalovirus promoter
(CMV). Plasmids pCMV-SB100X and pCMV-mSB also encode
active and inactive SB transposase genes and the plasmid
pCMV-Flpe expresses codon optimized Flp recombinase under
the control of the CMV promoter. (b) Colony forming assays
were performed in HeLa-cells. Equal molar ratios for plasmids
pAAV-SB100X, pAAV-SB100X-Flpe, pCMV-SB100X, pCMV-
mSB, pCMV-Flpe and pUC19 were used. Provided plasmid
combinations were co-transfected and two days post-
transfection cells were diluted and kept under selection
pressure for two weeks. Error bars indicate standard deviation
(n=3). *Significant difference between the group which received
Flpe (+Flpe) and the group without Flpe (-Flpe) (p-value <
0.05).
(TIFF)
Figure S3.  Flpe recombinase does not enhance
transposition efficiencies from AAV vector genomes. (a)
Transposon-substrates can be excised from AAV vector
genome by Flpe mediated recombination. The transposon-
donor vector AAV-transgene contains the transgene flanked by
transposon derived inverted repeats (IR) and Flpe recombinase
recognition sites FRT. This AAV vector was co-infected either
with a Flpe encoding vector (AAV-mSB-Flpe) or as a control
with the vector AAV-eGFP. After co-transduction into Huh7-
cells (left panel) and HEK293-cells (right panel), a 700 bp
fragment is PCR amplified if circularization occurred (black
arrows). Red arrows depict PCR primer binding sites for the
circularization PCR. (b) SB100X-HEK293 and mSB-HEK293
cells were co-infected with the recombinant vector AAV-neo at
MOI 10,000 and the previously published Flpe encoding high-
capacity adenoviral vector Ad5-mSB-Flpe. Two days post-
infection cells were diluted and kept under selection pressure
for two weeks. Error bars indicate standard deviation (n=3).
“n.s.”: not significant, no significant difference compared to the
control group (p-value > 0.05).
(TIFF)
Table S1.  Oligonucleotides used in this study.
(DOC)
Table S2.  Summary of the molecular analysis of cells
which received the inactive transposase (mSB).
(DOC)
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